Danaher 과거 수익 실적
과거 기준 확인 2/6
Danaher은 연평균 9.3%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 13.9%였습니다. 매출은 연평균 5.1%의 비율로 증가했습니다. Danaher의 자기자본이익률은 7.7%이고 순이익률은 16.6%입니다.
주요 정보
9.3%
수익 성장률
8.6%
EPS 성장률
| Life Sciences 산업 성장 | 21.5% |
| 매출 성장률 | 5.1% |
| 자기자본 수익률 | 7.7% |
| 순이익 | 16.6% |
| 최근 수익 업데이트 | 27 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Understanding Danaher's Cautiousness
Oct 25Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?
Sep 28
Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?
Sep 12Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?
Jun 23Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?
Jun 05Is Danaher (NYSE:DHR) A Risky Investment?
May 21It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
May 01Value Vs. Growth? Danaher Says Why Not Both?
Apr 25Danaher: All In On Life Sciences, And Market Update
Mar 27Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?
Mar 11Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings
Feb 10Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
Jan 30Is Danaher (NYSE:DHR) Using Too Much Debt?
Jan 12My Top 2024 Stock Pick: Danaher
Dec 27Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Nov 26RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing
Nov 19Why Danaher Is One Of My Favorite Long-Term Investments
Oct 26Danaher: Short-Term Headwinds, But Long-Term Tailwinds
Oct 17Should Danaher Investors Sell New Veralto Shares?
Oct 02Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price
Sep 30Danaher: A Lost Year
Aug 30Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens
Aug 02Danaher: A Compounding Icon At A Fair Price
Jul 25These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well
Jul 13Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Jun 28Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump
Jun 22At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?
Jun 15Danaher: A Great Chance To Buy This Long-Term Compounder
May 23With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case
Apr 26수익 및 비용 분석
수익 및 비용 분석
Danaher 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 27 Sep 24 | 23,742 | 3,934 | 7,470 | 1,549 |
| 28 Jun 24 | 23,568 | 4,056 | 7,358 | 1,528 |
| 29 Mar 24 | 23,737 | 4,069 | 7,281 | 1,498 |
| 31 Dec 23 | 23,890 | 4,200 | 7,245 | 1,503 |
| 29 Sep 23 | 21,026 | 4,408 | 6,080 | 1,332 |
| 30 Jun 23 | 23,065 | 5,019 | 6,489 | 1,390 |
| 31 Mar 23 | 24,904 | 5,757 | 6,762 | 1,460 |
| 31 Dec 22 | 26,643 | 6,222 | 7,080 | 1,528 |
| 30 Sep 22 | 31,250 | 6,640 | 8,572 | 1,787 |
| 01 Jul 22 | 30,816 | 6,206 | 8,489 | 1,808 |
| 01 Apr 22 | 30,283 | 6,206 | 8,369 | 1,803 |
| 31 Dec 21 | 24,802 | 5,283 | 6,763 | 1,498 |
| 01 Oct 21 | 28,065 | 5,636 | 7,818 | 1,643 |
| 02 Jul 21 | 26,720 | 5,361 | 7,543 | 1,544 |
| 02 Apr 21 | 24,799 | 4,595 | 7,278 | 1,441 |
| 31 Dec 20 | 22,284 | 3,510 | 6,880 | 1,348 |
| 02 Oct 20 | 20,392 | 3,083 | 6,354 | 1,246 |
| 03 Jul 20 | 18,886 | 2,853 | 5,954 | 1,186 |
| 03 Apr 20 | 18,034 | 2,614 | 5,659 | 1,146 |
| 31 Dec 19 | 17,911 | 2,364 | 5,577 | 1,126 |
| 27 Sep 19 | 15,562 | 2,093 | 4,709 | 980 |
| 28 Jun 19 | 16,037 | 2,145 | 4,880 | 998 |
| 29 Mar 19 | 16,573 | 2,166 | 5,125 | 1,028 |
| 31 Dec 18 | 17,049 | 2,406 | 5,356 | 1,059 |
| 28 Sep 18 | 19,615 | 2,761 | 6,246 | 1,211 |
| 29 Jun 18 | 19,290 | 2,669 | 6,173 | 1,189 |
| 30 Mar 18 | 18,819 | 2,553 | 6,072 | 1,160 |
| 31 Dec 17 | 15,519 | 2,172 | 5,012 | 956 |
| 29 Sep 17 | 17,828 | 2,360 | 5,764 | 1,098 |
| 30 Jun 17 | 17,432 | 2,191 | 5,633 | 1,060 |
| 31 Mar 17 | 17,164 | 2,051 | 5,536 | 1,016 |
| 31 Dec 16 | 16,882 | 2,153 | 5,481 | 975 |
| 30 Sep 16 | 16,621 | 1,927 | 5,362 | 943 |
| 01 Jul 16 | 16,001 | 1,905 | 5,218 | 914 |
| 01 Apr 16 | 13,663 | 1,775 | 4,549 | 788 |
| 31 Dec 15 | 14,434 | 1,747 | 4,635 | 861 |
| 02 Oct 15 | 15,335 | 1,875 | 4,769 | 926 |
| 03 Jul 15 | 16,530 | 2,177 | 4,865 | 1,002 |
| 03 Apr 15 | 19,186 | 2,521 | 5,348 | 1,143 |
| 31 Dec 14 | 12,867 | 1,639 | 3,953 | 769 |
| 26 Sep 14 | 19,197 | 2,683 | 5,305 | 1,189 |
| 27 Jun 14 | 19,159 | 2,599 | 5,311 | 1,210 |
| 28 Mar 14 | 19,336 | 2,583 | 5,405 | 1,267 |
| 31 Dec 13 | 18,283 | 2,591 | 5,042 | 1,104 |
양질의 수익: DHR 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: DHR 의 현재 순이익 이익률 (16.6%) 작년보다 낮습니다 (21%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: DHR 의 수입은 지난 5년 동안 매년 9.3% 씩 증가했습니다.
성장 가속화: DHR 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: DHR 은 지난 1년 동안 마이너스 수익 성장( -11% )을 기록하여 Life Sciences 업계 평균( -4.7% ).
자기자본 수익률
높은 ROE: DHR 의 자본 수익률( 7.7% )은 낮음으로 간주됩니다.